Press Release - Oslo, Norway, April 30, 2024: Photocure ASA (OSE: PHO), the
Bladder Cancer Company, announces its participation in the American Urological
Association Annual Congress (AUA 2024) to be held May 3-6, 2024 in San Antonio,
TX, USA.

Two AUA program highlights will feature Blue Light Cystoscopy with Cysview[®]
study data:

  · On Sunday, May 5[th], Dr. Sanjay Das will present the study, "Use of Blue
Light Cystoscopy Among Non-Muscle Invasive Bladder Cancer Patients and Outcomes
in an Equal Access setting: A Propensity Scored Matched Analysis"
The study, known as BRAVO (Bladder Cancer Recurrence Analysis in Veterans and
Outcomes), is a retrospective, propensity score matched analysis that evaluated
oncologic outcomes following BLC[®] compared to WLC alone in patients from the
Veterans Affairs (VA) Healthcare System.
(PD48: Bladder Cancer: Non-invasive III,
Sunday, May 5, 2024 1:00 PM to 3:00 PM, room 304A)

  · Monday, May 6[th], Poster presentation by Dr. Hailong Hu: "Blue Light
Cystoscopy versus White Light Cystoscopy for the Detection of Bladder Cancer
using modern HD 4K equipment: An Analysis of Pivotal Trial and Real-World Data".
This pooled meta-analysis includes data from a randomized clinical trial and a
supporting real-world evidence study conducted in China.
(MP71: Bladder Cancer: Non-invasive IV,
Monday, May 6, 2024 9:30 AM to 11:30 AM, room 302B)

AUA Congress attendees can meet the Photocure team on booth number 601 and gain
hands-on experience in the blue light cystoscopy with Cysview procedure using
the Saphira HD equipment.

Note to editors:

All trademarks mentioned in this release are protected by law and are registered
trademarks of Photocure ASA.
This press release may contain product details and information which are not
valid, or a product is not accessible, in your country. Please be aware that
Photocure does not take any responsibility for accessing such information which
may not comply with any legal process, regulation, registration or usage in the
country of your origin.

About Bladder Cancer

Bladder cancer ranks as the 8[th] most common cancer worldwide - the 5[th] most
common in men - with 1 949 000 prevalent cases (5-year prevalence rate)[1a],
614 000 new cases and more than 220 000 deaths in 2022.[1b]
Approx. 75% of all bladder cancer cases occur in men.[1] It has a high
recurrence rate with up to 61% in year one and up to 78% over five years.[2]
Bladder cancer has the highest lifetime treatment costs per patient of all
cancers.[3]
Bladder cancer is a costly, potentially progressive disease for which patients
have to undergo multiple cystoscopies due to the high risk of recurrence. There
is an urgent need to improve both the diagnosis and the management of bladder
cancer for the benefit of patients and healthcare systems alike.
Bladder cancer is classified into two types, non-muscle invasive bladder cancer
(NMIBC) and muscle-invasive bladder cancer (MIBC), depending on the depth of
invasion in the bladder wall. NMIBC remains in the inner layer of cells lining
the bladder. These cancers are the most common (75%) of all BC cases and include
the subtypes Ta, carcinoma in situ (CIS) and T1 lesions. In MIBC the cancer has
grown into deeper layers of the bladder wall. These cancers, including subtypes
T2, T3 and T4, are more likely to spread and are harder to treat.[4]

[1 ]Globocan. a) 5-year prevalence / b) incidence/mortality by population.
Available at: https://gco.iarc.fr/today, accessed [February 2024].
[2 ]Babjuk M, et al. Eur Urol. 2019